|
End-of-day quote
Shanghai S.E.
04/09/2026
|
5-day change | 1st Jan Change | ||
| 12.23 CNY | +0.08% |
|
+0.49% | +4.53% |
| 08-27 | Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 05-26 | Guizhou Sanli Pharmaceutical to Raise Up to 700 Million Yuan in Private Placement | MT |
Company Valuation: GuiZhou SanLi Pharmaceutical Co.,Ltd
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 8,252 | 6,483 | 5,637 | 7,738 | 5,205 | 4,735 |
| Change | - | -21.44% | -13.05% | 37.27% | -32.74% | -9.02% |
| Enterprise Value (EV) 1 | 7,872 | 6,041 | 5,212 | 7,670 | 5,313 | 5,084 |
| Change | - | -23.26% | -13.73% | 47.17% | -30.74% | -4.3% |
| P/E | 84.4x | 42.6x | 28x | 26.6x | 19.4x | 106x |
| PBR | 8.4x | 6.29x | 4.55x | 5.24x | 3.45x | 3.28x |
| PEG | - | 0.8x | 0.9x | 0.6x | -3.44x | -1.3x |
| Capitalization / Revenue | 13.1x | 6.9x | 4.69x | 4.73x | 2.43x | 2.78x |
| EV / Revenue | 12.5x | 6.43x | 4.34x | 4.69x | 2.48x | 2.99x |
| EV / EBITDA | 69.7x | 37x | 23.7x | 25.3x | 13.2x | 19.6x |
| EV / EBIT | 75.1x | 39.8x | 25.5x | 28.7x | 16.2x | 27.3x |
| EV / FCF | -133x | 110x | 40.8x | -209x | 54.4x | -88.4x |
| FCF Yield | -0.75% | 0.91% | 2.45% | -0.48% | 1.84% | -1.13% |
| Dividend per Share 2 | 0.25 | - | 0.1 | 0.2 | 0.34 | 0.06 |
| Rate of return | 1.23% | - | 0.73% | 1.06% | 2.62% | 0.51% |
| EPS 2 | 0.24 | 0.37 | 0.49 | 0.71 | 0.67 | 0.11 |
| Distribution rate | 104% | - | 20.4% | 28.2% | 50.7% | 54.5% |
| Net sales 1 | 630.2 | 939 | 1,201 | 1,635 | 2,144 | 1,703 |
| EBITDA 1 | 113 | 163.1 | 220.2 | 303.2 | 402.3 | 258.8 |
| EBIT 1 | 104.9 | 151.9 | 204.6 | 267.2 | 328.3 | 186.1 |
| Net income 1 | 93.95 | 152.3 | 201.3 | 292.7 | 274 | 46.25 |
| Net Debt 1 | -380.1 | -442.2 | -425.1 | -67.86 | 107.7 | 348.7 |
| Reference price 2 | 20.26 | 15.78 | 13.72 | 18.88 | 13.00 | 11.70 |
| Nbr of stocks (in thousands) | 407,322 | 410,862 | 410,862 | 409,862 | 400,382 | 404,740 |
| Announcement Date | 28/04/21 | 21/04/22 | 14/04/23 | 26/04/24 | 22/04/25 | 26/04/26 |
1CNY in Million2CNY
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 737M | |
| 32.72x | 11.9x | 24.26x | 0.6% | 1,024B | |
| 30.62x | - | - | 1.95% | 663B | |
| 32.73x | 7.6x | 15.8x | 2.67% | 453B | |
| 19.89x | 4.73x | 11.71x | 2.8% | 352B | |
| 22.72x | 5.84x | 14.51x | 2.7% | 304B | |
| 20.87x | 4.29x | 12.24x | 2.06% | 252B | |
| 27.66x | 7.14x | 13.15x | 2.31% | 236B | |
| 13.33x | 4.82x | 10.06x | 3.78% | 206B | |
| -46.14x | 6.65x | 25.95x | 2.18% | 187B | |
| Average | 17.16x | 6.62x | 15.96x | 2.34% | 367.91B | |
| Weighted average by Cap. | 24.05x | 7.99x | 17.80x | 1.95% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 603439 Stock
- Valuation GuiZhou SanLi Pharmaceutical Co.,Ltd
Select your edition
All financial news and data tailored to specific country editions
